Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transferring Early-stage Drug, Biologics Research From West To East Will Speed Up Over Next Five Years

This article was originally published in PharmAsia News

Executive Summary

BEIJING - A survey of leaders of U.S. pharmaceutical and biotech firms conducted by Citi Investment Research and Analysis indicates that outsourcing early-stage research to scientists at contract research organizations in China and India could see high-speed expansion over the next five years

You may also be interested in...



Chinese CRO ShangPharma Moving Into Biologics, Small-scale Manufacturing To Broaden Customer Pool

BEIJING - Limited-scale pharmaceutical manufacturing for research and biologics testing services are likely to become primary engines of expansion in the future for Chinese contract research organization ShangPharma, according to the Shanghai-based outfit's leadership

Chinese CRO ShangPharma Moving Into Biologics, Small-scale Manufacturing To Broaden Customer Pool

BEIJING - Limited-scale pharmaceutical manufacturing for research and biologics testing services are likely to become primary engines of expansion in the future for Chinese contract research organization ShangPharma, according to the Shanghai-based outfit's leadership

WuXi PharmaTech Founder Ge Li Says Upcoming Merger With Charles River Is Part Of Globalization Of The Drive To Save Lives

BEIJING - The chief executive officer of Shanghai-headquartered WuXi PharmaTech, Ge Li, said that a planned merger with Massachusetts-based contract research organization Charles River could help spark a "revolution" in early-stage drug research in China

UsernamePublicRestriction

Register

AP000837

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel